title: Endothelin-3: selectivity as an anti-aggregatory peptide in vivo.
abstract: Endothelin-3 (1 nmol/kg) given i.v. to anaesthetised rabbits significantly inhibited ADP-induced ex vivo platelet aggregation, while causing only a transient decrease in blood pressure and no change in heart rate. Pretreatment with piroxicam (14 mumol/kg) abolished the anti-aggregatory effect. Thus, endothelin-3, while not inhibiting rabbit platelets in vitro, can induce the release of a cyclo-oxygenase produce, probably prostacyclin, which inhibits ex vivo aggregation. Unlike endothelin-1, this was achieved with minimal effect on the haemodynamics.
authors.affiliation: William Harvey Research Institute, St. Bartholomew's Hospital Medical College, London, U.K.
authors.forename: P S
authors.initials: PS
authors.lastname: Lidbury
authors.forename: C
authors.initials: C
authors.lastname: Thiemermann
authors.forename: G R
authors.initials: GR
authors.lastname: Thomas
authors.forename: J R
authors.initials: JR
authors.lastname: Vane
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D016232:Endothelins; D006339:Heart Rate / Q000187:drug effects; D066298:In Vitro Techniques; D008297:Male; D010455:Peptides / Q000494:pharmacology*; D010894:Piroxicam / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors; D011817:Rabbits; D013997:Time Factors
chemical_list: D016232:Endothelins; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D010894:Piroxicam